Back to Search

A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies.

  • Protocol Number: 202412128
  • Principal Investigator: Kahl, Brad
  • Cancer Types: Leukemia, Myeloma, and Hematologic, Lymphoma

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.

Protocol Interventions

Drug: Sonrotoclax, Drug: Zanubrutinib